Category: Vaccine Headlines
Johns Hopkins Scientists Develop Nasal DNA Vaccine for Tuberculosis
Sci Tech Daily A new experimental vaccine takes aim at one of tuberculosis’s most stubborn defenses: the ability of bacteria to persist despite treatment. In a study published in the Journal of Clinical Investigation, researchers from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health report developing a therapeutic DNA vaccine delivered through the nose for tuberculosis (TB). The […]
Apr 8, 2026
Johns Hopkins Team Develops Therapeutic, Nasally Delivered DNA Vaccine for Tuberculosis
Newswise In a paper published today in the Journal of Clinical Investigation, a research team at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health reports developing a therapeutic intranasal (nose-delivered) DNA vaccine against tuberculosis (TB) that fuses two genes with the goal of directing the immune system to fight drug-tolerant bacterial “persisters” […]
Apr 1, 2026
Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole story
Fierce Biotech In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug program. But for Valneva CEO Thomas Lingelbach, the regulatory future of the company’s Pfizer-partnered Lyme disease vaccine, VLA15, is very much “a matter of negotiation.” “It’s a matter of bringing all the […]
Apr 1, 2026
US left without functioning vaccine panel as adviser says ‘drama distracts’
The Guardian Move comes after judge voided Kennedy’s ACIP picks, leaving key flu, Covid and RSV vaccines in limbo. Amid upheaval to the US vaccine advisory committee Robert Malone, the former co-chair and controversial figure who has opposed vaccines, says he has been pushed out and will not be involved in any future decisions. The move comes […]
Mar 25, 2026
Phase III TB vaccines and MDR-TB treatments
Clinical Trials Arena GlobalData epidemiologists project TB cases across the 16 major markets to reach 4.5 million by 2033. It has been several years since a new tuberculosis (TB) drug advanced into Phase III trials, but momentum in the field is now picking up, with a vaccine and two novel treatments progressing through late-stage studies. […]
Mar 25, 2026
Scientists Can Finally Explain Rare Blood Clots Linked to COVID Vaccines
Science Alert COVID vaccines saved millions of lives, but months into the rollout, a small number of people began developing dangerous blood clots in unusual parts of the body. These only happened after vaccines that used a modified adenovirus to deliver their payload, such as the AstraZeneca vaccine. Why these blood clots formed was a […]
Mar 11, 2026
RFK Jr.’s advisers had a plan to target covid shots. Then it fell apart.
Washington Post Some members of the CDC’s vaccine advisory panel have publicly questioned the safety and manufacturing of the shots, including raising a debunked theory that DNA contaminants in the vaccines are harmful. A key federal vaccine advisory panel has abandoned an attack on the covid-19 mRNA vaccines — a shift that comes as some […]
Mar 11, 2026
Universal flu vaccine: How scientists are closing in on the virus’s ‘weak spots’
BBC While current flu shots need to be updated each season, scientists are finding new ways to make vaccine that could last much longer and cover more strains. Each year, roughly a billion people around the world catch the flu. You’ll know if you’ve got it – it can knock you out for a week or […]
Mar 4, 2026
RNA vaccine funding cuts threaten decades of scientific progress
CIDRAP Federal investment in RNA vaccine research has supported nearly three decades of scientific work spanning infectious diseases, cancer, and vaccine development, but recent and proposed funding cuts threaten to stall that progress, according to a cross-sectional study published yesterday in JAMA Network Open. Led by a team at Northwestern University, researchers identified 178 active National Institutes of […]
Mar 4, 2026
FDA reversal on mRNA-1010 could transform the seasonal influenza vaccines market
Global Data Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010. This announcement comes one week after the FDA’s Center for Biologics Evaluation and Research (CBER) notified Moderna that it would not initiate a review of mRNA-1010, and a Refusal-to-File (RTF) letter was issued, citing concerns over […]
Feb 25, 2026